Skip NavigationSkip to Content
Return Return to Search Results

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial

  1. Author:
    Ledgerwood, J. E.
    Pierson, T. C.
    Hubka, S. A.
    Desai, N.
    Rucker, S.
    Gordon, I. J.
    Enama, M. E.
    Nelson, S.
    Nason, M.
    Gu, W. J.
    Bundrant, N.
    Koup, R. A.
    Bailer, R. T.
    Mascola, J. R.
    Nabel, G. J.
    Graham, B. S.
    Team, V. R. C. S.

  2. Author Address

    [Ledgerwood, JE; Hubka, SA; Desai, N; Rucker, S; Gordon, IJ; Enama, ME; Bundrant, N; Koup, RA; Bailer, RT; Mascola, JR; Nabel, GJ; Graham, BS; VRC 303 Study Team] NIAID, VRC, NIH, Bethesda, MD 20892 USA [Pierson, TC; Nelson, S] NIAID, Viral Pathogenesis Sect, Viral Dis Lab, NIH, Bethesda, MD 20892 USA [Nason, M] NIAID, Biostat Res Branch, Div Clin Res, NIH, Bethesda, MD 20892 USA [Gu, WJ] NCI, Biostat Res Branch, SAIC Frederick Inc, Frederick, MD 21701 USA;Ledgerwood, JE (reprint author), NIAID, VRC, NIH, 9000 Rockville Pike,CRC Bldg 10,Room 5-2440, Bethesda, MD 20892 USA;ledgerwood@mail.nih.gov
    1. Year: 2011
    2. Date: May
  2. Journal: Journal of Infectious Diseases
    1. 203
    2. 10
    3. Pages: 1396-1404
  4. Type of Article: Article
  5. ISSN: 1537-6613
  1. Abstract:

    Methods. A DNA vaccine encoding the protein premembrane and the E glycoproteins of the NY99 strain of WNV under the transcriptional control of the CMV/R promoter was evaluated in an open-label study in 30 healthy adults. Half of the subjects were age 18-50 years and half were age 51-65 years. Immune responses were assessed by enzyme-linked immunosorbent assay, neutralization assays, intracellular cytokine staining, and ELISpot. Results. The 3-dose vaccine regimen was safe and well tolerated. Vaccine-induced T cell and neutralizing antibody responses were detected in the majority of subjects. The antibody responses seen in the older age group were of similar frequency, magnitude, and duration as those seen in the younger cohort. Conclusions. Neutralizing antibody responses to WNV were elicited by DNA vaccination in humans, including in older individuals, where responses to traditional vaccine approaches are often diminished. This DNA vaccine elicited T cell responses of greater magnitude when compared with an earlier-generation construct utilizing a CMV promoter. Clinical Trials Registration. NCT00300417.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1093/infdis/jir054
  3. View record in Web of Science®
  4. WOS: 000289838800007

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel